A dual FXR–TGR5 agonist decreased the histologic features of NASH in an obese mouse model (118); therefore, BA-induced amelioration of high-fat–induced NAFLD is considered to be mediated via FXR and TGR5. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.